---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016068"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:15:47.165472+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics reports Q2 net loss of $16.9M; IND cleared for lead candidate JANX007

## Summary
- Net loss $16.9M vs $6.2M in Q2 2021; R&D expenses rose to $14.1M from $4.7M.
- Cash and short-term investments $354.3M (Dec 31, 2021: $375.0M).
- FDA cleared IND for JANX007 (PSMA-TRACTr) for mCRPC; Phase 1 trial expected 2H 2022.
- IND submission for JANX008 (EGFR-TRACTr) on track for 2H 2022; TROP2-TRACTr IND planned for 2023.
- First TRACIr candidate (PD-L1xCD28) IND-enabling studies ongoing; IND submission expected 2023.

## SEC filing metadata
- accession: 0000950170-22-016068
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017022016068/0000950170-22-016068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017022016068/janx-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016068
- JSON: https://secwatch.observer/filing/0000950170-22-016068.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.